A revolutionary blood cancer treatment that genetically modifies patient cells to fight the disease cuts the risk of it progressing by 74%, a world-first clinical trial has found.
The therapy, ciltacabtagene autoleucel, “significantly slows or stops progression” of multiple myeloma in patients who have stopped responding to other treatments, according to the study. The results were presented in Chicago at the American Society of Clinical Oncology’s (Asco) annual meeting, the world’s largest cancer conference.
